BioSpace News Archive

The global microarray market size was USD 3.99 Billion in 2021 and is expected to register a revenue CAGR of 8.31% during the forecast period, according to latest analysis by Emergen Research.

The U.S. Food and Drug Administration issued warning letters to four companies for illegally selling honey-based products that may pose a significant health risk to consumers.

The global Adenosine Triphosphate (ATP) Test Kit market size is estimated to be worth US$ 196.5 million in 2021 and is forecast to a readjusted size of US$ 359.4 million by 2030 with a CAGR of 8.9% during the forecast period 2022-2030.

A recent report provides crucial insights along with application based and forecast information in the Global Alvimopan Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market.

The global Pharmaceutical Ethanol market size is estimated to be worth US$ 1224 million in 2021 and is forecast to a readjusted size of US$ 1091.8 million by 2030 with a CAGR of -1.6% during the forecast period 2022-2030.

The global Famciclovir API market size is estimated to be worth US$ 13 million in 2021 and is forecast to a readjusted size of US$ 15 million by 2030 with a CAGR of 2.3% during the forecast period 2022-2030.

Vascular Dynamics, Inc. (VDI), a privately held medical device company focused on developing game-changing endovascular device-based solutions for patients suffering from heart failure, has announced the closing of its $20 million financing round led by an investment partner of VDI shareholder Rainbow Medical.

Many cancer patients show no symptoms at early stages and receive diagnoses at advanced stages, which can drastically attenuate treatment effectiveness and decrease their quality of life.

Spiderwort Inc., the biotech company innovating in cellulose-based tissue scaffolding to treat acute spinal cord injuries, announced the successful completion of its $13.2 million USD Series A financing.

Eko, a digital health company advancing heart and lung disease detection, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Eko Murmur Analysis Software (EMAS) for detecting and characterizing murmurs found in adults and pediatric patients.